ArticleBMC cancer2026
Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
aimsThe role of adjuvant therapy for hepatocellular carcinoma (HCC) patients with high recurrence risks after curative resection remains controversial. This study aimed to assess the efficacy and safety of postoperative adjuvant transarterial chemoembolization (TACE) combined with lenvatinib (LEN) and immune checkpoint inhibitors (ICIs) for these patients.
methodsThis multicenter, retrospective study included histologically confirmed HCC patients with high recurrence risks after curative resection during December 2015 and December 2023. Baseline differences were balanced between patients who received postoperative adjuvant TACE (TACE group) and TACE combined with LEN and ICIs (TACE-LEN-ICI group) by propensity score matching (PSM). The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included overall survival (OS) and safety.
resultsAmong 517 patients included in the analysis, 418 patients in TACE group and 99 patients in TACE-LEN-ICI group. After PSM, the TACE-LEN-ICI group had longer median RFS (HR = 0.69, 95% CI, 0.50–0.96, 34.0 vs. 18.8 months, P = 0.026) and OS (HR = 0.54, 95% CI 0.33–0.90, unreached vs. 81.6 months, P = 0.016) than TACE group. The 1-/2-/3-year RFS rates were 80.8%, 60.6%, and 42.5% in the TACE-LEN-ICI group and 60.1%, 46.9%, and 40.2% in the TACE group, respectively. The 1-/2-/5-year OS rates were 97.0%, 87.6%, and 54.4% in the TACE-LEN-ICI group and 85.9%, 70.7%, and 56.9% in the TACE group, respectively. Grade 3–4 adverse events occurred in 37 patients (37.4%) in TACE-LEN-ICI group, with no treatment-related death in both groups.
conclusionsPostoperative adjuvant TACE-LEN-ICI treatment appears safe and may offer survival benefits to HCC patients with high recurrence risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.